Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23888657 | 0.95 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8063903 | 0.93 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8333329 | 0.93 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL21596444 | 0.93 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL19865819 | 0.89 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28354803 | 0.87 | LMNA (0.40) | LMNACA12CA1CA2CA3 | |
| SCHEMBL20761405 | 0.84 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL26231525 | 0.83 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL23030500 | 0.82 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| SCHEMBL27043456 | 0.82 | LMNA (0.44) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4198037-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230148590-A1 | Aqueous Formulations of Dicamba | BASF CORPORATION | 2023-05-18 | — | — | US | disclosed |
| EP-4125365-A1 | AQUEOUS FORMULATIONS OF DICAMBA | BASF Corporation (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115426880-A | Aqueous formulations of dicamba | 巴斯夫公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021198458-A1 | AQUEOUS FORMULATIONS OF DICAMBA | BASF CORPORATION (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-1606253-A4 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEUVLINIC ACID ESTERS WITH NITRO COMPOUNDS | DU PONT (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7244443-B2 | Polymers of fluorinated monomers and hydrophilic monomers | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1606253-A1 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEUVLINIC ACID ESTERS WITH NITRO COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004085390-A1 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEUVLINIC ACID ESTERS WITH NITRO COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148590-A1 | Aqueous Formulations of Dicamba | BOLA2; BOLA2B, CIP2A, AQP1 | LMNA 1513/4885CA12 354/4885CA1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.